VRCA Verrica Pharmaceuticals
- 8.180
- -0.600-6.83%
- 8.170
- -0.010-0.12%
Verrica Pharmaceuticals News
Verrica Pharmaceuticals Inc.'s (NASDAQ:VRCA) CEO Will Probably Find It Hard To See A Huge Raise This Year
Key Insights Verrica Pharmaceuticals' Annual General Meeting to take place on 6th of June Total pay for CEO Ted White includes US$600.6k salary The overall pay is comparable to the industry averag
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
WEST CHESTER, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical
Needham Reiterates Buy on Verrica Pharmaceuticals, Maintains $16 Price Target
Needham analyst Serge Belanger reiterates Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and maintains $16 price target.
Analysts Offer Insights on Healthcare Companies: Xtant Medical Holdings (XTNT) and Verrica Pharmaceuticals (VRCA)
Verrica Pharmaceuticals Amends Global Trial and Equity Terms
Verrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement With Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH for the Treatment of Common Warts
Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1st half of 2025 Amendment should benefit both parties from a cost and time to market
Verrica Pharmaceuticals Shares Are Trading Higher Are Trading Higher Possibly Amid Strength in High-short Interest Stocks After Retail Trader 'Roaring Kitty' Returned to Social Media. Also, Needham and HC Wainwright Raised Their Respective Price...
Verrica Pharmaceuticals Shares Are Trading Higher Are Trading Higher Possibly Amid Strength in High-short Interest Stocks After Retail Trader 'Roaring Kitty' Returned to Social Media. Also, Needham an
Planet Fitness To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Roth MKM cu
Insiders the Biggest Winners as Verrica Pharmaceuticals Inc.'s (NASDAQ:VRCA) Market Cap Rises to US$406m
Key Insights Verrica Pharmaceuticals' significant insider ownership suggests inherent interests in company's expansion The top 2 shareholders own 53% of the company Institutions own 17% of Verric
Verrica Pharmaceuticals Price Target Raised to $14.00/Share From $13.00 by HC Wainwright & Co.
Verrica Pharmaceuticals Price Target Raised to $14.00/Share From $13.00 by HC Wainwright & Co.
HC Wainwright & Co. : The Verrica Pharmaceuticals (VRCA.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $13.00 to $14.00.
HC Wainwright & Co. : The Verrica Pharmaceuticals (VRCA.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $13.00 to $14.00.
Verrica Pharmaceuticals Is Maintained at Buy by Needham
Verrica Pharmaceuticals Is Maintained at Buy by Needham
Needham Maintains Buy on Verrica Pharmaceuticals, Raises Price Target to $16
Needham analyst Serge Belanger maintains Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and raises the price target from $8 to $16.
Verrica Pharmaceuticals Inc (VRCA) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Buy Rating Affirmed for Verrica Pharmaceuticals on Strong Ycanth Sales and Strategic Growth Prospects
Stocks With More Than 10% Short Interest - Finviz Screener
Verrica Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Revenue Results.
Verrica Pharmaceuticals Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Revenue Results.
Strong Buy Rating for Verrica Pharmaceuticals as Ycanth Launch Exceeds Expectations
Verrica Pharmaceuticals | 10-Q: Quarterly report
Verrica Pharmaceuticals (VRCA.US): The 2024 Q1 financial report achieved revenue of US$3.826 million, with a previous value of US$37,000, with an expected value of US$2.78 million; earnings per share of -0.38 USD, previous value of -0.13 USD, and expected
Verrica Pharmaceuticals (VRCA.US): The 2024 Q1 financial report achieved revenue of US$3.826 million, with a previous value of US$37,000, with an expected value of US$2.78 million; earnings per share of -0.38 USD, previous value of -0.13 USD, and expected value of -0.40 USD.
Analysis
Price Target
No Data
